Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.40 |
| ▸ | MAOB | P27338 | 3/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8863992 | 0.91 | CA2 (0.47) | CA2CYP2D6ALDH1A1CYP3A4TSHR | |
| SCHEMBL1018563 | 0.87 | CA2 (0.48) | CA2CYP2D6ALDH1A1CYP3A4TSHR | |
| SCHEMBL4295393 | 0.83 | CA2 (0.50) | CA2CYP2D6ALDH1A1CYP3A4TSHR | |
| SCHEMBL1136635 | 0.83 | CA2 (0.50) | CA2CYP2D6ALDH1A1CYP3A4TSHR | |
| SCHEMBL1136638 | 0.83 | CA2 (0.50) | CA2CYP2D6ALDH1A1CYP3A4TSHR | |
| SCHEMBL6348557 | 0.83 | CA2 (0.68) | CA2CYP2D6ALDH1A1CYP3A4TSHR | |
| SCHEMBL4970970 | 0.83 | CA2 (0.68) | CA2CYP2D6ALDH1A1CYP3A4TSHR | |
| SCHEMBL13230301 | 0.83 | CA2 (0.51) | CA2CYP2D6ALDH1A1CYP3A4TSHR | |
| SCHEMBL7346088 | 0.83 | CA2 (0.68) | CA2CYP2D6ALDH1A1CYP3A4TSHR | |
| SCHEMBL9370374 | 0.82 | MAOB (0.39) | CA2CYP2D6ALDH1A1CYP3A4TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110105462-A1 | MODULATORS OF DOPAMINE NEUROTRANSMISSION | NSAB, FILIAL AF NEUROSEARCH SWEDEN AB, SVERIGE (DK) | 2011-05-05 | — | — | US | disclosed |
| EP-2271635-A1 | MODULATORS OF DOPAMINE NEUROTRANSMISSION | NSAB, Filial af NeuroSearch Sweden AB, Sverige (DK) | 2011-01-12 | — | — | EP | disclosed |
| WO-2009133109-A1 | MODULATORS OF DOPAMINE NEUROTRANSMISSION | NSAB, FILIAL AF NEUROSEARCH SWEDEN AB, SVERIGE (DK) | 2009-11-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105462-A1 | MODULATORS OF DOPAMINE NEUROTRANSMISSION | DBH, SLC18A2, SLC6A3 | CA2 3728/4885CYP2D6 697/4885ALDH1A1 1056/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.